Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure.

[1]  A. Ferreira,et al.  Cholesterol--a marker of nutritional status in mild to moderate heart failure. , 2008, International journal of cardiology.

[2]  G. Fonarow,et al.  Albumin levels predict survival in patients with systolic heart failure. , 2008, American heart journal.

[3]  P. Sbragia,et al.  Usefulness of serum albumin concentration for in-hospital risk stratification in frail, elderly patients with acute heart failure. Insights from a prospective, monocenter study. , 2008, International journal of cardiology.

[4]  M. Laakso,et al.  Prognostic role of pro‐ and anti‐inflammatory cytokines and their polymorphisms in acute decompensated heart failure , 2008, European journal of heart failure.

[5]  A. Jánosi,et al.  Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.

[6]  W. R. MacLellan,et al.  Atorvastatin and statins in the treatment of heart failure , 2007, Expert opinion on pharmacotherapy.

[7]  P. Poole‐Wilson,et al.  Altered intestinal function in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.

[8]  G. Fonarow,et al.  CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Reverse Epidemiology beyond Dialysis Patients: Chronic Heart Failure, Geriatrics, Rheumatoid Arthritis, COPD, and AIDS , 2007, Seminars in dialysis.

[9]  G. Fonarow,et al.  An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. , 2007, American heart journal.

[10]  G. Fonarow,et al.  Total cholesterol levels and mortality risk in nonischemic systolic heart failure. , 2006, American heart journal.

[11]  B. Horne,et al.  Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. , 2006, The American journal of cardiology.

[12]  W. Grimm,et al.  Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. , 2006, European heart journal.

[13]  J. Cohn,et al.  C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan , 2005, Circulation.

[14]  W John Boscardin,et al.  Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. , 2005, JAMA.

[15]  Lynn A Smaha,et al.  The American Heart Association Get With The Guidelines program. , 2004, American heart journal.

[16]  L. Tavazzi,et al.  Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure , 2004, European journal of heart failure.

[17]  Kamyar Kalantar-Zadeh,et al.  Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. , 2004, Journal of the American College of Cardiology.

[18]  R. Gliklich,et al.  Get With the Guidelines for Cardiovascular Secondary Prevention , 2004 .

[19]  S. Anker,et al.  The relationship between cholesterol and survival in patients with chronic heart failure. , 2003, Journal of the American College of Cardiology.

[20]  R. Gliklich,et al.  Using "get with the guidelines" to improve cardiovascular secondary prevention. , 2003, Joint Commission journal on quality and safety.

[21]  G. Fonarow,et al.  Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. , 2002, Journal of cardiac failure.

[22]  G. Fonarow,et al.  The relationship between obesity and mortality in patients with heart failure. , 2001, Journal of the American College of Cardiology.

[23]  Anita Deswal,et al.  Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.

[24]  S. Anker,et al.  Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. , 2000, International journal of cardiology.

[25]  S. Anker,et al.  The endotoxin-lipoprotein hypothesis , 2000, The Lancet.

[26]  P. Poole‐Wilson,et al.  Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. , 2000, Circulation.

[27]  K. Labresh,et al.  Get with the guidelines. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[28]  K. Kataoka,et al.  Serial circulating concentrations of c‐reactive protein, interleukin (il)‐4, and il‐6 in patients with acute left heart decompensation , 1999, Clinical cardiology.

[29]  Josef Niebauer,et al.  Endotoxin and immune activation in chronic heart failure: a prospective cohort study , 1999, The Lancet.

[30]  O. Faergeman,et al.  The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. , 1997, Journal of cardiac failure.

[31]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.

[32]  N. Mittman,et al.  Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  A J Belanger,et al.  Epidemiology of heart failure. , 1991, American heart journal.

[34]  J Pekkanen,et al.  Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. , 1990, The New England journal of medicine.